Skip to content

Zepbound vs Ozempic: which is for what?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Zepbound vs Ozempic: the two aren't approved for the same thing. Ozempic (semaglutide) is FDA-approved for adults with type 2 diabetes. Zepbound (tirzepatide) is approved for weight reduction and obstructive sleep apnea in adults. Self-pay costs $349 a month for the Ozempic 1 mg pen and $399 to $449 for Zepbound vials at 5 mg and above.

Source: NovoCare self-pay

Key takeaways

  • Ozempic and Zepbound are different molecules from different companies, with no overlap in approved uses.
  • All of Ozempic's approved uses are in adults with type 2 diabetes. It has no weight-loss use.
  • Zepbound is approved for long-term weight reduction and sleep apnea in adults with obesity. It isn't approved for blood sugar control.
  • A plan that covers Ozempic for diabetes may still exclude Zepbound. Ask about each brand separately.
  • Paying cash? The Ozempic 1 mg pen is $349 a month through NovoCare. Zepbound 5 mg vials are $399 through LillyDirect.

Ozempic vs Zepbound, side by side

From each FDA label and our verified price records
OzempicZepbound
Active ingredientsemaglutidetirzepatide
MakerNovo NordiskEli Lilly and Company
FDA-approved uses
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (injection and tablets)
  • Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (injection)
  • Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events (tablets)
  • Reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease (injection)
  • reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition
  • moderate to severe obstructive sleep apnea (OSA) in adults with obesity
How it is takenweekly (multi-dose pen); daily (tablet)weekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)
Strengths0.25 to 9 mg2.5 to 15 mg
Label starting dose
  • 0.25 mg weekly
  • 1.5 mg daily
  • 2.5 mg weekly
Cheapest verified self-payNo self-pay price listed$449 per fill at 15 mg
LillyDirect self-pay
With covering commercial insuranceNo savings-card price listed$25 with the manufacturer card
Medicare GLP-1 BridgeNoYes: KwikPen (multi-dose, 4 weekly doses)
LabelRevised: 5/2026 (DailyMed version 20)Revised: 8/2026 (DailyMed version 40)
Ozempic: most common reactions on the label · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionOzempic 1 mgPlacebo
Nausea20.3%6.1%
Vomiting9.2%2.3%
Diarrhea8.8%1.9%
Abdominal pain5.7%4.6%
Constipation3.1%1.5%
Zepbound: most common reactions on the label · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
Reaction15 mgPlacebo
Nausea28%8%
Diarrhea23%8%
Vomiting13%2%
Constipation11%5%
Abdominal Pain10%5%
Dyspepsia10%4%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Ozempic and Zepbound get compared all the time, usually by people who want to lose weight and have heard both names. The starting point is plain: these are two different medicines approved for two different conditions. Ozempic is semaglutide from Novo Nordisk, for type 2 diabetes. Zepbound is tirzepatide from Eli Lilly, for weight reduction and sleep apnea. Which one a prescriber can write on-label (for a use the FDA approved), and which one a plan will pay for, follows from that.

Which one suits whom?

  • You have type 2 diabetes and want blood sugar control. Ozempic is labeled for it, along with cardiovascular risk reduction and, for the injection, kidney risk reduction in adults with type 2 diabetes and chronic kidney disease. Zepbound isn’t approved for blood sugar control. The tirzepatide brand that is labeled for diabetes is Mounjaro.
  • You’re being treated for weight. Zepbound is approved to reduce excess body weight and keep it off long term in adults with obesity, or with overweight and at least one weight-related condition. Ozempic has no weight-loss use. The semaglutide brand that does is Wegovy.
  • You have moderate to severe obstructive sleep apnea with obesity. Zepbound has that use.
  • You’re on Medicare. Ozempic for diabetes goes through Part D. Zepbound has a Part D route for sleep apnea and a Bridge route for weight management.

If you came here choosing between these two for weight loss, the first thing to ask your prescriber is whether you have a use on either label. If you have type 2 diabetes and also want treatment for weight, ask how the two labels apply to you, and whether a brand with both molecules’ other label, Mounjaro or Wegovy, belongs in the conversation.

What is each one approved for?

Every approved use of Ozempic is in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, reducing the risk of major adverse cardiovascular events (serious heart and blood vessel events), and (injection) reducing the risk of kidney disease getting worse and cardiovascular death in those who also have chronic kidney disease.

Zepbound’s two approved uses are long-term weight reduction in adults with obesity or overweight with a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. Its label says to use it with a reduced-calorie diet and increased physical activity.

There’s no overlap between the two lists.

How do the doses and devices compare?

Both are injected under the skin once weekly, at any time of day, with or without meals. That’s what they share. The dose numbers belong to different medicines and can’t be mapped onto each other.

Ozempic comes in 0.25 mg, 0.5 mg, 1 mg, 2 mg. The label starts at 0.25 mg for 4 weeks, moves to 0.5 mg, and allows 1 mg and then 2 mg if more blood sugar control is needed, with at least 4 weeks at each step.

Zepbound comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The label starts at 2.5 mg for 4 weeks, moves to 5 mg, and allows 2.5 mg increases after at least 4 weeks on each dose. The recommended maintenance dosage (the dose you stay on) for weight reduction is 5 mg, 10 mg or 15 mg.

The devices are different too.

  • Ozempic pen. Multi-dose. At a steady dose, one pen covers four weekly injections, and needles come with it.
  • Zepbound vial. Single-dose, drawn up with a syringe. The label says to use a new syringe and needle each time. This is the main self-pay form.
  • Zepbound KwikPen. One pen with four weekly doses. You buy pen needles separately.

See the dosing guide for each ladder and the pen vs vial vs pill comparer for the forms.

What do the labels report about weight?

This is the question behind most searches for this pair, so here’s what the records hold, and why it can’t be turned into a ranking.

The Ozempic label reports weight as a result within its diabetes trials. In a 30-week trial in adults with type 2 diabetes where Ozempic was the only diabetes medicine, the mean (average) changes from baseline were -1.2 kg with placebo, -3.8 kg with Ozempic 0.5 mg and -4.7 kg with 1 mg.

The Zepbound label reports weight as its primary result. In Study 1, in adults with obesity or overweight and without diabetes, weight was assessed after 72 weeks. Mean change was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg, versus -3.1% with placebo. In Study 2, in adults with type 2 diabetes, it was -12.8% with 10 mg and -14.7% with 15 mg, versus -3.2%.

One set of figures is in kilograms over 30 weeks in people with diabetes at diabetes doses. The other is in percent over 72 weeks, in one trial of people without diabetes and one of people with it. They measure different things. We make no claim about which produces more weight loss.

What does each one cost?

Here are the prices on each route:

Ozempic (NovoCare self-pay). $199 a month for a new patient’s first two fills of 0.25 mg or 0.5 mg, then $349. The 1 mg pen is $349 and the 2 mg pen is $499. The list price (the full price before any discount) is $1,027.51 per pen.

Zepbound (LillyDirect self-pay, vial or KwikPen). $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg through 15 mg. For 7.5 mg and above, you keep that price only if you refill within 45 days of getting the previous fill. Otherwise, 7.5 mg costs $499 and the three highest doses cost $699. The single-dose pen lists at $1,086.37 per fill.

Savings cards. With commercial insurance that covers the drug, each card lowers a fill to as little as $25. Only Zepbound’s card has an offer for commercially insured people whose plan doesn’t cover it: $499 a month for the single-dose pen, which is more than the self-pay vial.

A year at a steady dose on self-pay comes to $4,537 for Ozempic 1 mg and $5,837 for Zepbound 10 mg vials refilled on time. The cost calculator handles other doses, and the Ozempic cost and Zepbound cost pages have every route.

How do insurance and Medicare treat them?

Commercial plans. Insurers check the diagnosis against the label. Ozempic is commonly covered for type 2 diabetes, often with prior authorization (the plan’s approval before it pays). Zepbound is assessed under weight-management or sleep apnea criteria, and a plan that covers Ozempic may exclude Zepbound altogether. Call the number on your insurance card and ask about each brand separately. The insurance guide and appeal letter generator can help after a denial.

Medicare. CMS lists type 2 diabetes as an indication eligible for Part D coverage, which is the route for Ozempic. CMS says Medicare generally does not cover GLP-1 drugs for the weight loss indication, but names Zepbound for moderate to severe obstructive sleep apnea in adults with obesity as coverable under Part D. For weight management, the Medicare GLP-1 Bridge covers the Zepbound KwikPen at a $50 copay for those who qualify. Ozempic isn’t a Bridge product, and people with type 2 diabetes aren’t eligible for the Bridge. See does Medicare cover Zepbound.

How do the side effects compare?

Both labels have a boxed warning about the risk of thyroid C-cell tumors, and both report mostly gastrointestinal (stomach and bowel) reactions. Each table below describes its own drug in its own trials. Because the people, doses and trial lengths differ, the rates aren’t a ranking.

Ozempic. In two placebo-controlled trials in adults with type 2 diabetes (mean exposure 32.9 weeks), nausea was reported by 15.8 percent of patients on 0.5 mg and 20.3 percent on 1 mg, against 6.1 percent on placebo. Constipation was reported by 5 percent and 3.1 percent, against 1.5 percent. Gastrointestinal reactions overall occurred in 32.7% and 36.4% of patients, compared with 15.3% on placebo.

Zepbound. In the pool of two weight-reduction trials in adults with obesity or overweight (up to 72 weeks), nausea was reported by 25, 29 and 28 percent of patients on 5 mg, 10 mg and 15 mg, against 8 percent on placebo. Constipation was reported by 17, 14 and 11 percent, against 5 percent. Gastrointestinal reactions overall occurred in 56% of patients on each dose, compared with 30% on placebo.

If you take insulin or a sulfonylurea (a type of diabetes medicine), both labels say your prescriber should consider lowering the dose of that medicine to reduce the risk of low blood sugar. In the Zepbound trial in people with type 2 diabetes, hypoglycemia (low blood sugar) occurred in 10.3% of those also taking a sulfonylurea and 2.1% of those not taking one. The side effects guide explains the other warnings.

Switching between Ozempic and Zepbound

A switch from Ozempic to Zepbound is a change of molecule and usually a change of approved use, so it starts with a new prescription for an approved use. The Zepbound label gives no instructions for moving from another GLP-1 medicine and states only its starting dose. The Ozempic injection label likewise has none for the reverse move. No label converts a dose of one into a dose of the other.

The Zepbound label does say that coadministration with any GLP-1 receptor agonist is not recommended, so the two aren’t taken together. Your prescriber decides the timing and starting dose. Our page on switching from Ozempic to Zepbound sets out both labels and the cost on each side, and the switching planner covers other pairs.

Frequently asked questions

Are Zepbound and Ozempic the same drug?

No. They're different molecules from different companies. Ozempic is semaglutide, made by Novo Nordisk, and its label covers type 2 diabetes in adults. Zepbound is tirzepatide, made by Eli Lilly, and its label covers long-term weight reduction and moderate to severe obstructive sleep apnea in adults with obesity. Doses, devices, prices and coverage all differ.

Is Ozempic or Zepbound better for weight loss?

Only Zepbound is approved for weight reduction. Ozempic has no weight-loss use. Past that, the labels don't support a ranking. Ozempic's trials were in people with type 2 diabetes over 30 to 40 weeks and reported weight in kilograms. Zepbound's weight trials ran 72 weeks.

Ozempic vs Zepbound: which costs less?

On self-pay, the Ozempic pen is $349 a month at 1 mg and $499 at 2 mg. Zepbound vials or KwikPen are $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above when you refill within 45 days. With covered commercial insurance, each savings card goes as low as $25.

Can I switch from Ozempic to Zepbound?

A prescriber can make that change, but the Zepbound label gives no instructions for switching from another GLP-1 medicine. It gives only its starting dose, 2.5 mg once weekly, and no label converts an Ozempic dose into a Zepbound dose. The Zepbound label also says it isn't recommended with any GLP-1 receptor agonist, so the two aren't overlapped.

Will insurance cover Zepbound if it covers Ozempic?

Not necessarily. Plans judge each drug by its approved use. Ozempic is covered as a type 2 diabetes medicine. Zepbound falls under weight-management benefits, which some plans exclude, or under its sleep apnea use. On Medicare, Ozempic goes through Part D, while Zepbound for weight management is available only through the Bridge, as the KwikPen, to people who qualify.

Sources (27)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  2. 2.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.”
  3. 3.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND once weekly at any time of day, with or without meals.”
  4. 4.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region.”
  5. 5.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.”
  6. 6.
    FDA label (DailyMed): Ozempic prescribing information, section 3
    “Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens”
  7. 7.
    FDA label (DailyMed): Ozempic prescribing information, Instructions for Use
    “NovoFine® Plus 32G 4 mm disposable needles are included with your OZEMPIC pen.”
  8. 8.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
  9. 9.
    FDA label (DailyMed): Zepbound prescribing information, section 2.2
    “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
  10. 10.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Administer ZEPBOUND in combination with a reduced-calorie diet and increased physical activity.”
  11. 11.
    FDA label (DailyMed): Ozempic prescribing information, section 14.1
    “The mean changes from baseline to week 30 were -1.2 kg, -3.8 kg and -4.7 kg in the placebo, OZEMPIC 0.5 mg, and OZEMPIC 1 mg arms, respectively.”
  12. 12.
    FDA label (DailyMed): Zepbound prescribing information, section 14.1
    “In both trials, weight reduction was assessed after 72 weeks of treatment (at least 52 weeks at maintenance dose).”
  13. 13.
    FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 2
    “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”
  14. 14.
    FDA label (DailyMed): Zepbound prescribing information, section 7.1
    “ZEPBOUND lowers blood glucose. When initiating ZEPBOUND, consider reducing the dose of concomitantly administered insulin or insulin secretagogues (e.g., sulfonylureas) to reduce the risk of hypoglycemia [see Warnings and Precautions (5.7)].”
  15. 15.
    FDA label (DailyMed): Ozempic prescribing information, section 7.1
    “When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
  16. 16.
    FDA label (DailyMed): Zepbound prescribing information, section 5.7
    “In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%).”
  17. 17.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  18. 18.
    CMS: Information for Part D Plans
    “Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
  19. 19.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.